Maravai LifeSciences
MRVI
184 hedge funds and large institutions have $292M invested in Maravai LifeSciences in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 61 increasing their positions, 51 reducing their positions, and 41 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
23% more call options, than puts
Call options by funds: $1.82M | Put options by funds: $1.49M
20% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 51
0% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 41
1% less funds holding
Funds holding: 185 → 184 (-1)
7.14% less ownership
Funds ownership: 99.29% → 92.15% (-7.1%)
62% less capital invested
Capital invested by funds: $769M → $292M (-$477M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
+$29.6M |
| 2 |
PCM
Philosophy Capital Management
Alamo,
California
|
+$10.2M |
| 3 |
Two Sigma Advisers
New York
|
+$7.99M |
| 4 |
Two Sigma Investments
New York
|
+$5.24M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$29M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$17.5M |
| 3 |
Jennison Associates
New York
|
-$16.3M |
| 4 |
JP Morgan Chase
New York
|
-$14.1M |
| 5 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$12.2M |
MRVI Hedge Fund Activity: Q1 2025 in Review
184 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q1 2025, worth a combined $292M — down 62% from $769M a quarter earlier.
Fund positioning in MRVI was balanced in Q1 2025: 41 funds opened new positions, 41 closed out, 61 added to existing stakes and 51 trimmed.
The largest buyer was Mirabella Financial Services, opening a new position worth an estimated $29.6M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $29M sold.
- 184 institutional investors held Maravai LifeSciences (MRVI) as of Q1 2025, down from 185 in Q4 2024.
- Funds reported $292M of Maravai LifeSciences stock for Q1 2025, down 62% quarter-over-quarter.
- 41 funds opened new Maravai LifeSciences positions in Q1 2025 and 41 closed out, a net change of 0 holders.
- The largest Maravai LifeSciences buyer in Q1 2025 was Mirabella Financial Services, an estimated $29.6M added.
- The largest Maravai LifeSciences seller in Q1 2025 was Alyeska Investment Group, an estimated $29M sold.
Based on aggregated 13F filings for Q1 2025.